Amgen’s Riabni™ (rituximab-arrx), a biosimilar for Rituxan® (rituximab – Genentech and Biogen), is now FDA approved to for use with methotrexate to treat moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to one or more tumor necrosis factor antagonist therapies.

• The FDA first approved Riabni in 2020 to treat certain adults diagnosed with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s granulomatosis), and microscopic polyangiitis.
• Riabni’s recommended dosing for RA is two 1,000mg intravenous infusions separated by two weeks (one treatment course) every 24 weeks. If appropriate based on clinical evaluation, the time between treatment courses can be shortened to as little as 16 weeks.